亚洲伤寒沙门菌抗菌药物耐药性监测:2016-2019年SEAP项目
SEAP项目在孟加拉国、尼泊尔和巴基斯坦招募8705例血培养确诊伤寒病例,分析抗菌药物耐药性。结果显示伤寒沙门菌耐药广泛,巴基斯坦出现XDR株,而副伤寒沙门菌耐药率低。
要点
- 伤寒沙门菌对氟喹诺酮类非敏感率高达87%-98%,巴基斯坦XDR株占64%。
- 孟加拉国和尼泊尔未报告MDR副伤寒沙门菌,巴基斯坦仅2%副伤寒分离株为MDR。
核心结论
- 三个国家副伤寒沙门菌耐药率低,但伤寒沙门菌耐药广泛,包括氟喹诺酮类非敏感和巴基斯坦XDR株出现,限制了治疗选择。
研究设计与样本
- SEAP项目2016年9月至2019年9月在孟加拉国、尼泊尔和巴基斯坦招募各年龄段疑似或血培养确诊伤寒的发热患者,共纳入8705例血培养确诊菌株。
主要发现
- 8705例中孟加拉国4873例(56%),尼泊尔1602例(18%),巴基斯坦2230例(26%);7591例(87%)为伤寒沙门菌,1114例(13%)为副伤寒沙门菌。
- 孟加拉国MDR伤寒沙门菌占17%(701/4065),尼泊尔占1%(19/1342),巴基斯坦占16%(331/2084);巴基斯坦XDR占64%(1319/2074)。
- 伤寒沙门菌氟喹诺酮类非敏感率:孟加拉国98%,尼泊尔87%,巴基斯坦95%。
- 巴基斯坦3例(2%)副伤寒沙门菌为MDR,孟加拉国和尼泊尔未报告MDR副伤寒沙门菌。
临床怎么用
- 在伤寒沙门菌耐药率高的地区,经验性治疗需考虑当地耐药谱,氟喹诺酮类可能不可靠。
- 巴基斯坦出现XDR伤寒沙门菌,应加强监测并依据药敏结果调整治疗方案。
- 伤寒结合疫苗(TCV)推广期间应持续监测耐药变化,并为无疫苗的副伤寒沙门菌耐药监测提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinicians have limited therapeutic options for enteric as a result of increasing antimicrobial resistance, and therefore typhoid vaccination is recommended as a preventive measure. As a part of the Surveillance for Enteric Fever in Asia Project (SEAP), we investigated the extent measured the burden of antimicrobial resistance (AMR) among confirmed enteric fever cases in Bangladesh, Nepal, and Pakistan. METHODS: From September 2016-September 2019, SEAP recruited study participants of all age groups from its outpatient, inpatient, hospital laboratory, laboratory network, and surgical sites who had a diagnosis of febrile illness that was either suspected or blood culture confirmed for enteric fever. Antimicrobial resistance of isolates was determined by disc diffusion using Clinical and Laboratory Standard Institute cut-off points. We reported the frequency of multidrug resistance (MDR)(resistance to ampicillin, cotrimoxazole, and chloramphenicol), extensive drug resistance (XDR) (MDR plus non-susceptible to fluoroquinolone and any 3rd generation cephalosporins), and fluoroquinolone (FQ) and azithromycin non-susceptibility. RESULTS: We enrolled 8,705 blood culture confirmed enteric fever cases: 4,873 (56%) from Bangladesh, 1,602 (18%) from Nepal and 2,230 (26%) from Pakistan. Of these, 7,591 (87%) were Salmonella Typhi and 1114 (13%) were S. Paratyphi. MDR S. Typhi was identified in 17% (701/4065) of isolates in Bangladesh, and 1% (19/1342) in Nepal. In Pakistan, 16 % (331/2084) of S. Typhi isolates were MDR, and 64% (1319/2074) were XDR. FQ nonsusceptibility among S. Typhi isolates was 98% in Bangladesh, 87% in Nepal, and 95% in Pakistan. Azithromycin non-susceptibility was detected in 77 (2%) in Bangladesh, 9 (.67%) in Nepal and 9 (.59%) isolates in Pakistan. In Pakistan, three (2%) S. Paratyphi isolates were MDR; no MDR S. Paratyphi was reported from Bangladesh or Nepal. CONCLUSIONS: Although AMR against S. Paratyphi was low across the three countries, there was widespread drug resistance among S. Typhi, including FQ non-susceptibility and the emergence of XDR S. Typhi in Pakistan, limiting treatment options. As typhoid conjugate vaccine (TCV) is rolled out, surveillance should continue to monitor changes in AMR to inform policies and to monitor drug resistance in S. Paratyphi, for which there is no vaccine.
引用
- Qamar FN, Yousafzai MT, Dehraj IF, et al. Antimicrobial Resistance in Typhoidal Salmonella: Surveillance for Enteric Fever in Asia Project, 2016-2019. Clin Infect Dis. 2020. PMID: 33258934. doi:10.1093/cid/ciaa1323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。